Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates

Jamie Renbarger, Alexander Aleksic, Leticia McGuffey, Robert Dauser, Stacey Berg, Susan Blaney

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: SU5416 is a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR. The role of this agent in brain tumors is currently being investigated. Pharmacokinetic studies of SU5416 have been performed in humans; however, there have been no studies of its penetration in the cerebrospinal fluid (CSF). We studied the pharmacokinetics of SU5416 in plasma and CSF after intravenous (i.v.) administration using a nonhuman primate model that is highly predictive of the CSF penetration in humans. Experimental design: SU5416 (85 mg/m2, about 3.8 mg/kg) was administered i.v. over 20 min to four nonhuman primates. Serial plasma and CSF samples were obtained prior to, during, and after completion of the infusion for determination of SU5416 concentrations. SU5416 was measured in plasma and CSF using high-performance liquid chromatography (HPLC). Concentration-versus-time data were modeled using model-independent and model-dependent methods. Results: Peak plasma concentrations ranged from 6.3 to 14.5 μM and the mean plasma AUC was 620 ± 180 μM·min. Disappearance of SU5416 from the plasma was best described by a one-compartment model with a half-life of 39 ± 2.9 min. The volume of distribution was 36 ± 11 l/m2 and the clearance was 0.62 ± 0.2 l/min per m2. SU4516 was not quantifiable in the CSF. Conclusions: There is minimal penetration of SU5416 into the CSF after i.v. administration. The very low CNS exposure to SU5416 after i.v. dosing suggests that this agent is not optimal for the treatment of leptomeningeal tumors.

Original languageEnglish (US)
Pages (from-to)39-42
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume53
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Cerebrospinal fluid
Pharmacokinetics
Intravenous Administration
Primates
Cerebrospinal Fluid
Plasmas
Tumors
Semaxinib
Vascular Endothelial Growth Factor Receptor-2
High performance liquid chromatography
Brain Neoplasms
Protein-Tyrosine Kinases
Design of experiments
Area Under Curve
Half-Life
Brain
Research Design
High Pressure Liquid Chromatography
Molecules

Keywords

  • Antiangiogenesis
  • Leptomeningeal malignancy
  • SU5416

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. / Renbarger, Jamie; Aleksic, Alexander; McGuffey, Leticia; Dauser, Robert; Berg, Stacey; Blaney, Susan.

In: Cancer Chemotherapy and Pharmacology, Vol. 53, No. 1, 01.2004, p. 39-42.

Research output: Contribution to journalArticle

Renbarger, Jamie ; Aleksic, Alexander ; McGuffey, Leticia ; Dauser, Robert ; Berg, Stacey ; Blaney, Susan. / Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. In: Cancer Chemotherapy and Pharmacology. 2004 ; Vol. 53, No. 1. pp. 39-42.
@article{e142a90c29af4d108ef8d18c1d4e6179,
title = "Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates",
abstract = "Purpose: SU5416 is a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR. The role of this agent in brain tumors is currently being investigated. Pharmacokinetic studies of SU5416 have been performed in humans; however, there have been no studies of its penetration in the cerebrospinal fluid (CSF). We studied the pharmacokinetics of SU5416 in plasma and CSF after intravenous (i.v.) administration using a nonhuman primate model that is highly predictive of the CSF penetration in humans. Experimental design: SU5416 (85 mg/m2, about 3.8 mg/kg) was administered i.v. over 20 min to four nonhuman primates. Serial plasma and CSF samples were obtained prior to, during, and after completion of the infusion for determination of SU5416 concentrations. SU5416 was measured in plasma and CSF using high-performance liquid chromatography (HPLC). Concentration-versus-time data were modeled using model-independent and model-dependent methods. Results: Peak plasma concentrations ranged from 6.3 to 14.5 μM and the mean plasma AUC was 620 ± 180 μM·min. Disappearance of SU5416 from the plasma was best described by a one-compartment model with a half-life of 39 ± 2.9 min. The volume of distribution was 36 ± 11 l/m2 and the clearance was 0.62 ± 0.2 l/min per m2. SU4516 was not quantifiable in the CSF. Conclusions: There is minimal penetration of SU5416 into the CSF after i.v. administration. The very low CNS exposure to SU5416 after i.v. dosing suggests that this agent is not optimal for the treatment of leptomeningeal tumors.",
keywords = "Antiangiogenesis, Leptomeningeal malignancy, SU5416",
author = "Jamie Renbarger and Alexander Aleksic and Leticia McGuffey and Robert Dauser and Stacey Berg and Susan Blaney",
year = "2004",
month = "1",
doi = "10.1007/s00280-003-0683-z",
language = "English (US)",
volume = "53",
pages = "39--42",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates

AU - Renbarger, Jamie

AU - Aleksic, Alexander

AU - McGuffey, Leticia

AU - Dauser, Robert

AU - Berg, Stacey

AU - Blaney, Susan

PY - 2004/1

Y1 - 2004/1

N2 - Purpose: SU5416 is a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR. The role of this agent in brain tumors is currently being investigated. Pharmacokinetic studies of SU5416 have been performed in humans; however, there have been no studies of its penetration in the cerebrospinal fluid (CSF). We studied the pharmacokinetics of SU5416 in plasma and CSF after intravenous (i.v.) administration using a nonhuman primate model that is highly predictive of the CSF penetration in humans. Experimental design: SU5416 (85 mg/m2, about 3.8 mg/kg) was administered i.v. over 20 min to four nonhuman primates. Serial plasma and CSF samples were obtained prior to, during, and after completion of the infusion for determination of SU5416 concentrations. SU5416 was measured in plasma and CSF using high-performance liquid chromatography (HPLC). Concentration-versus-time data were modeled using model-independent and model-dependent methods. Results: Peak plasma concentrations ranged from 6.3 to 14.5 μM and the mean plasma AUC was 620 ± 180 μM·min. Disappearance of SU5416 from the plasma was best described by a one-compartment model with a half-life of 39 ± 2.9 min. The volume of distribution was 36 ± 11 l/m2 and the clearance was 0.62 ± 0.2 l/min per m2. SU4516 was not quantifiable in the CSF. Conclusions: There is minimal penetration of SU5416 into the CSF after i.v. administration. The very low CNS exposure to SU5416 after i.v. dosing suggests that this agent is not optimal for the treatment of leptomeningeal tumors.

AB - Purpose: SU5416 is a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR. The role of this agent in brain tumors is currently being investigated. Pharmacokinetic studies of SU5416 have been performed in humans; however, there have been no studies of its penetration in the cerebrospinal fluid (CSF). We studied the pharmacokinetics of SU5416 in plasma and CSF after intravenous (i.v.) administration using a nonhuman primate model that is highly predictive of the CSF penetration in humans. Experimental design: SU5416 (85 mg/m2, about 3.8 mg/kg) was administered i.v. over 20 min to four nonhuman primates. Serial plasma and CSF samples were obtained prior to, during, and after completion of the infusion for determination of SU5416 concentrations. SU5416 was measured in plasma and CSF using high-performance liquid chromatography (HPLC). Concentration-versus-time data were modeled using model-independent and model-dependent methods. Results: Peak plasma concentrations ranged from 6.3 to 14.5 μM and the mean plasma AUC was 620 ± 180 μM·min. Disappearance of SU5416 from the plasma was best described by a one-compartment model with a half-life of 39 ± 2.9 min. The volume of distribution was 36 ± 11 l/m2 and the clearance was 0.62 ± 0.2 l/min per m2. SU4516 was not quantifiable in the CSF. Conclusions: There is minimal penetration of SU5416 into the CSF after i.v. administration. The very low CNS exposure to SU5416 after i.v. dosing suggests that this agent is not optimal for the treatment of leptomeningeal tumors.

KW - Antiangiogenesis

KW - Leptomeningeal malignancy

KW - SU5416

UR - http://www.scopus.com/inward/record.url?scp=0742269443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742269443&partnerID=8YFLogxK

U2 - 10.1007/s00280-003-0683-z

DO - 10.1007/s00280-003-0683-z

M3 - Article

C2 - 14551735

AN - SCOPUS:0742269443

VL - 53

SP - 39

EP - 42

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -